Prostate Cancer - Ittmann Lab Prostate cancer is the most common visceral malignancy and the second leading cause of cancer death among U.S. males, with over 29,000 deaths in 2004 attributable to this ...

Each year, approximately 250,000 men in the U.S. receive a prostate cancer diagnosis. While most cases have low morbidity and mortality rates, a subset of cases demands aggressive treatment.

Whole-gland ablation isn't recommended if you have high-risk prostate cancer. High-risk means you have a Gleason score of 8-10 or a prostate-specific antigen (PSA) score above 20.

Men assessed as healthy after a pathologist analyzes their tissue sample may still have an early form of prostate cancer.

Dr. Neal Patel says biopsy results may not fully capture prostate cancer risk, stressing that PSA, stage and disease volume ...

A new urology lab with advanced diagnostic testing is up and running at UPMC St. Margaret Hospital to deal with a slow but steady increase in the number of prostate cancer cases diagnosed each ...

It's natural to have questions about a prostate exam. Here, a Tufts University chair of urology gently walks you through the experience.

In June this year, Paul Henderson received test results showing elevated PSA levels. In this weekly diary, he will be sharing ...

The Fundamentals of Prostate Health What exactly is the prostate? This walnut-sized gland sits below the bladder and produces seminal fluid that nourishes and transports sperm.

Prostate cancer is the second-leading cause of cancer-associated death in men after lung cancer. Prostate cancer is highly common in which 1 in 8 men will be diagnosed with the disease in their ...

Dr. Fulgham: An enlarged prostate is a common consequence of aging, and a fairly high percentage of men in their 50s, 60s, and 70s have symptoms of an enlarged prostate, but there's no evidence ...

High-intensity-focused ultrasound (HIFU) can treat some men with prostate cancer as an alternative to surgery or radiation therapy. The corresponding study was published in The Lancet. "We believe ...